BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 10674975)

  • 1. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
    Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
    Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
    Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T; Kees M; Gisslinger H
    Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
    Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
    Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
    Rojewski MT; Körper S; Schrezenmeier H
    Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
    Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
    Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T; Westervelt P; Hess JL
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalase activity and arsenic sensitivity in acute leukemia.
    Coe E; Schimmer AD
    Leuk Lymphoma; 2008 Oct; 49(10):1976-81. PubMed ID: 18949620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
    Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
    Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
    Alemany M; Levin J
    Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
    Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
    Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
    Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P
    J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.